991 studies found for:    Graft-versus-host disease
Show Display Options
Rank Status Study
1 Active, not recruiting Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Graft Versus Host Disease;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Waldenström Macroglobulinemia
Interventions: Drug: rituximab;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Drug: anti-thymocyte globulin;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis;   Biological: graft versus host disease prophylaxis/therapy;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: busulfan;   Radiation: total-body irradiation;   Biological: graft-versus-tumor induction therapy;   Biological: immunosuppressive therapy
2 Enrolling by invitation Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease
Conditions: Graft Versus Host Disease;   Ophthalmologic Complications
Interventions: Biological: graft versus host disease prophylaxis/therapy;   Other: questionnaire administration;   Procedure: optical coherence tomography
3 Not yet recruiting Carfilzomib for the Prevention of Graft Versus Host Disease
Condition: Graft-versus-host Disease
Intervention: Drug: carfilzumib
4 Recruiting Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease
Conditions: Acute Graft-versus-Host Disease;   Allogeneic Stem Cell Transplant
Intervention: Procedure: Blood samples
5 Recruiting Prevention of Ocular Graft-Versus Host Disease With Topical Cyclosporine in Recipients of Allogeneic Hematopoietic Stem Cell Transplants Performed With a Reduced Intensity Conditioning Regimen
Condition: Ocular Graft Versus Host Disease
Intervention: Drug: Topical Ocular Cyclosporine
6 Terminated
Has Results
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
Condition: Graft Versus Host Disease
Interventions: Drug: Visilizumab;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Antithymocyte globulin (ATG)
7 Completed Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
Conditions: Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions: Biological: alemtuzumab;   Drug: methylprednisolone;   Drug: prednisone;   Other: flow cytometry;   Other: immunologic technique;   Other: pharmacological study
8 Unknown  Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Conditions: Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: methotrexate;   Drug: rasburicase;   Drug: sirolimus;   Drug: tacrolimus;   Other: diagnostic laboratory biomarker analysis;   Other: flow cytometry;   Other: immunologic technique;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
9 Completed Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant
Condition: Cancer
Interventions: Biological: graft versus host disease prophylaxis/therapy;   Genetic: fluorescence in situ hybridization;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: in vitro-treated bone marrow transplantation;   Procedure: management of therapy complications
10 Recruiting Safety and Efficacy of UC-MSC in Patients With Acute Severe Graft-versus-host Disease
Condition: Acute GVH Disease
Intervention: Biological: Human Umbilical Cord Derived MSC
11 Recruiting Mesenchymal Stromal Cells for Acute Graft Versus Host Disease
Condition: Acute GVH Disease
Intervention: Biological: Mesenchymal stromal cell therapy
12 Unknown  Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
Conditions: Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma;   Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Intervention: Drug: pentostatin
13 Recruiting Mesenchymal Stem Cells as a Treatment for Oral Complications of Graft-versus-host Disease
Condition: Graft -Versus-host-disease
Intervention: Biological: Mesenchymal stromal cells
14 Recruiting Clobetasol for Oral Graft-Versus-Host Disease
Condition: Oral Chronic Graft vs Host Disease
Interventions: Drug: Clobetasol Oral Rinse;   Procedure: Chronic GVHD organ staging;   Procedure: Assessment of Oral GVHD;   Behavioral: Numeric rating scales for oral pain;   Behavioral: Oral Global Scale;   Behavioral: Painometer (POM) Assessment;   Behavioral: Oral Health Impact Profile-OHIP-14;   Procedure: Biopsy of buccal mucosa;   Procedure: Short ACTH stimulation test
15 Completed Experience of Having Chronic Graft-Versus-Host Disease
Condition: Graft-Versus-Host Disease
Interventions: Behavioral: Interview;   Behavioral: Questionnaire
16 Completed Voriconazole Pharmacokinetics in Children With Gastrointestinal Graft Versus Host Disease
Conditions: Graft Versus Host Disease;   Stem Cell Transplantation
Intervention: Drug: voriconazole
17 Recruiting Mesenchymal Stem Cells for Treatment of Refractory Acute Graft-versus-host Disease
Condition: Acute Graft-versus-host Disease
Interventions: Biological: Mesenchymal stem cells;   Biological: Non-mesenchymal stem cells
18 Recruiting Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host Disease
Condition: Chronic Graft-versus-host Disease
Interventions: Biological: Mesenchymal stem cells;   Biological: Non-mesenchymal stem cells
19 Recruiting Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease
Conditions: Graft Versus Host Disease;   Steroid Refractory GVHD;   Acute GVH Disease
Intervention: Drug: Infliximab and Basiliximab
20 Completed Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease
Condition: Graft Versus Host Disease
Interventions: Drug: cyclosporine;   Drug: hydroxychloroquine;   Drug: prednisone;   Drug: tacrolimus

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years